NCT06904066 2026-03-18
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
13 trialsNCT04848064 2026-02-10
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06934382 2025-12-26
24CT015
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT07300683 2025-12-24
FRACTALL
University College, London
Phase 1 Recruiting
NCT03690011 2025-10-23
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Baylor College of Medicine
Phase 1 Recruiting
NCT04318678 2025-10-23
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT03081910 2025-09-04
MAGENTA
Baylor College of Medicine
Phase 1 Recruiting
NCT06462365 2025-04-15
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Phase 1 Recruiting
NCT06909474 2025-04-03
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT04972942 2025-03-13
ALLO-T-DART
New York Medical College
Phase 1 Recruiting
NCT06136364 2023-11-18
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1 Recruiting
NCT05995028 2023-10-12
Universal 4SCAR7U Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1 Recruiting
NCT05043571 2021-09-14
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
National University Hospital, Singapore
Phase 1 Recruiting